Landmark deal paves way for cheaper HIV/ Aids protection jab

A new drug will be provided to prevent HIV at a lower cost in more than 100 low-income countries within two years-a step expected to provide millions of access to penetration therapy and the world may try to finish HIV/AIDS.

The drug, called LenacAPAVIR and is managed by injection, will be released early this year, at a cost of $ 28,000 (20,000 pounds) per person annually.

But Wednesday’s announcement is to reduce this price to only $ 40 – about 0.1 % of the original cost. The low -cost version will be launched in 2027 over 120 low -income and medium countries.

Scientists say that the drug prevents the virus from repeating the inner cells.

Former US President Bill Clinton mediated the deal to provide the cheapest antiviral drugs for people with HIV in developing countries after negotiations with pharmaceutical companies.

The agreement announced on Wednesday was reached between the Clinton Foundation in partnership with the Gates Foundation and other groups, including the South African Research Institute and Whitz Rey.

Lenacapavir achieved the results of a wonderful trial, and in July, he received official support from the World Health Organization for HIV.

The injection is taken twice a year and provides six months of protection against HIV infection simultaneously.

Experts say long -acting injections such as Lenacapavir can help reduce new infections in the most vulnerable population, including girls, teenage girls, homosexuals, sex workers, and those who use drugs.

It is hoped that it will replace the current form of the preventive drug in HIV, or know that it is preparatory, or prevent exposure before exposure, which is taken orally and also costs $ 40 per person each year.

Birth control pills are taken daily, which may be difficult for patients to consume, and can carry shame in certain societies. Daily dose makes it difficult to reach. According to Gates, only 18 % of those who can benefit from Prep have current access.

Lenacapavir has already been approved by the US Food and Drug Administration and the European Commission this year.

Last year, the American pharmaceutical company Gilead announced that the experience of HIV drugs has achieved a 100 % success rate.

The new public version is still awaiting organizational approval, but it is hoped that it will be available within 18 months.

One study says that increased access to injections to only 4 % of the population can prevent up to 20 % of new HIV infections.

The drug can be used to protect people from hunting the virus, but also to treat those who have, according to scientists.

This advertisement comes amid a troubled year for global health, especially anti -HIV and AIDS, after discounts in the US government’s external aid program, the US Agency for International Development, under Trump’s management.

According to AIDS movies, more than 40 million people are currently living with HIV.

Despite the huge steps taken to reduce HIV and AIDS -related death rates since 2000, about 1.3 million people are still contracting HIV last year, and more than 600,000 people died due to AIDS diseases.

South Africa is still the country that has the largest number of HIV, where nearly eight million people live with the virus. It will be one of the countries that can reach the new drug.

Participated in additional reports by Aksa and Andira in Nairobi